Oryzon Getting $300,000 to Continue Developing Alzheimer’s Therapy ORY-2001

Oryzon Getting $300,000 to Continue Developing Alzheimer’s Therapy ORY-2001
Oryzon Genomics is receiving $300,000 from the Alzheimer's Drug Discovery Foundation to continue developing its Alzheimer's treatment ORY-2001. In exchange, the foundation, which has been a longtime partner of Oryzon, will receive shares of the company's stock. Oryzon develops epigenetics therapies, which regulate genome function without affecting the makeup of genes themselves. "Regulation of gene transcription has emerged as a key biological determinant of protein production and cellular differentiation and plays a significant pathogenic role in a number of human diseases," it said. The company is wrapping up a Phase 1 clinical trial of ORY-2001 at a university hospital in Barcelona. It is evaluating the treatment's effectiveness, safety, tolerability and pharmacokinetics of the therapy in healthy people, including older adults. Pharmacokinetics refers to a drug's movement through the body. Oryzon, which discussed the Phase 1 trial at the Alzheimer's & Parkinson's Diseases Congress in Vienna in March, is also doing pre-clinical trial studies of ORY-2001's potential to treat neurodegenerative diseases. Those studies, in mouse models of Alzheimer's, have shown that ORY-2001 improved cognitive function, restored memory loss, and changed gene expression in the hippocampus area of the brain. The $300,000 in foundation financing is for a Phase 2 clinical trial of ORY-2001 that the company expec
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *